Cyanine5 DBCO

Cat. # Quantity Price Lead time
A30F0 1 mg $125 in stock
B30F0 5 mg $260 in stock
C30F0 10 mg $325 in stock
D30F0 25 mg $510 in stock
E30F0 50 mg $895 in stock
F30F0 100 mg $1490 in stock
Found better price? Let us know and we will propose the way forward!

A derivative of Cyanine5 red-emitting fluorophore possessing DBCO (dibenzocyclooctyne, also known as ADIBO, azodibenzocyclooctyne) group for copper free click chemistry.

Strained cycloalkynes, such as cyclooctynes, react with azides very rapidly in the absence of copper catalyst in a strain-promoted alkyne-azide cycloaddition (SPAAC). This reaction is very fast, mild, and biocompatible.

Compared to other cycloalkynes, DBCO provide among the fastest reaction kinetics, still possessing good stability.

Absorption and emission spectra of Cyanine5

Absorption and emission spectra of Cyanine5

Customers also purchased with this product

sulfo-Cyanine3 amine

Water soluble cyanine dye with bright fluorescence and high extinction coefficient. Contains an amino group for the conjugation with electrophiles and enzymatic transamination labeling.

Azidobutyric acid NHS ester

Activated NHS ester for azido-labeling of peptides and proteins.

BDP 558/568 tetrazine

Stable fluorophore that can be conjugated with trans-cyclooctene derivatives of biomolecules for their visualization.

General properties

Appearance: dark blue solid
Mass spec M+ increment: 928.4
Molecular weight: 929.03
Molecular formula: C53H59N4F6O2P
Solubility: good in DMF, DMSO, chlorinated organic solvents, practically insoluble in water (<1 uM, < 1 mg/L)
Quality control: NMR 1H, HPLC-MS (95%)
Storage conditions: Storage: 12 months after receival at -20°C in the dark. Transportation: at room temperature for up to 3 weeks. Avoid prolonged exposure to light. Desiccate.
MSDS: Download
Product specifications

Spectral properties

Excitation/absorption maximum, nm: 646
ε, L⋅mol−1⋅cm−1: 250000
Emission maximum, nm: 662
Fluorescence quantum yield: 0.2

Product citations

  1. Toro-González, M.; Akingbesote, N.; Bible, A.; Sanders, B.; Ivanov, A.S.; Jansone-Popova, S.; Popovs, I.; Benny, P.; Perry, R.; Davern, S. Development of 225 Ac-doped Biocompatible Nanoparticles for Targeted Alpha Therapy. Research Square, 2024, preprint. doi: 10.21203/rs.3.rs-3921227/v1
  2. Wang, Y.-J.; Li, L.; Yu, J.; Hu, H.-Y.; Liu, Z.-X.; Jiang, W.-J.; Xu, W.; Guo, X.-P.; Wang, F.-S.; Sheng, J.-Z. Imaging of Escherichia Coli K5 and Glycosaminoglycan Precursors via Targeted Metabolic Labeling of Capsular Polysaccharides in Bacteria. Sci. Adv., 2023, 9(7), eade4770. doi: 10.1126/sciadv.ade4770
  3. Borner, T.; Tinsley, I. C.; Milliken, B. T.; Doebley, S. A.; Najjar, N. R.; Kerwood, D. J.; De Jonghe, B. C.; Hayes, M. R.; Doyle, R. P. Creation of a Peptide Antagonist of the GFRAL–RET Receptor Complex for the Treatment of GDF15-Induced Malaise. J. Med. Chem., 2023, 66(16), 11237–11249. doi: 10.1021/acs.jmedchem.3c00667
  4. Miranda, A.; Lopez-Blanco, R.; Lopes-Nunes, J.; Melo, A.M.; Campello, M.P.C.; Paulo, A.; Oliveira, M.C.; Mergny, J.-L.; Oliveira, P.A.; Fernandez-Megia, E.; Cruz, C. Gallic Acid–Triethylene Glycol Aptadendrimers Synthesis, Biophysical Characterization and Cellular Evaluation. Pharmaceutics, 2022, 14(11), 2456. doi: 10.3390/pharmaceutics14112456
Show more (4)
Your item has been added. View your cart or proceed to checkout
The count of items is incorrect.